Hetastarch — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV	10-20 mL/kg	Administered as a bolus or infusion over 15-30 minutes; may repeat if needed, but maximum daily dose is 20-40 mL/kg	Duration: As needed for resuscitation; usually given once or twice Notes: Use with caution in patients with coagulopathies or renal disease. Monitor central venous pressure and urine output.
Cat	IV	5-10 mL/kg	Administered as a bolus or infusion over 15-30 minutes; may repeat if needed, but maximum daily dose is 20 mL/kg	Duration: As needed for resuscitation; usually given once or twice Notes: Cats are more sensitive to volume overload; use lower doses and monitor closely.
Horse	IV	10-20 mL/kg	Administered as an infusion over 30-60 minutes; may repeat if needed, but maximum daily dose is 20-40 mL/kg	Duration: As needed for resuscitation; usually given once or twice Notes: Monitor for signs of volume overload and coagulopathy. Use with caution in horses with renal disease.
Cattle	IV	10-20 mL/kg	Administered as an infusion over 30-60 minutes; may repeat if needed, but maximum daily dose is 20-40 mL/kg	Duration: As needed for resuscitation; usually given once or twice Notes: Use with caution in animals with coagulopathies. Monitor for volume overload.
Small Ruminants	IV	10-20 mL/kg	Administered as an infusion over 30-60 minutes; may repeat if needed, but maximum daily dose is 20-40 mL/kg	Duration: As needed for resuscitation; usually given once or twice Notes: Use with caution in animals with coagulopathies. Monitor for volume overload.
Rabbit	IV	5-10 mL/kg	Administered as a slow bolus or infusion over 15-30 minutes; may repeat if needed	Duration: As needed for resuscitation Notes: Rabbits are prone to cardiovascular stress; use lower doses and monitor closely.
Bird/Poultry	IV	5-10 mL/kg	Administered as a slow bolus or infusion over 15-30 minutes; may repeat if needed	Duration: As needed for resuscitation Notes: Limited data; use with caution and monitor for volume overload.
Exotic/Other	IV	5-10 mL/kg	Administered as a slow bolus or infusion over 15-30 minutes; may repeat if needed	Duration: As needed for resuscitation Notes: Dose based on extrapolation from other species; use with caution.

Clinical Indications & Species Uses

General Indications

Plasma volume expansion
Fluid resuscitation in hypovolemic states

Dog (Canine)

Treatment of hypovolemia
Shock (hemorrhagic, septic, traumatic)
Hypoproteinemia (as an adjunct to crystalloids)
Improvement of microcirculation in pancreatitis
Prevention of hypotension during anesthesia

Cat (Feline)

Treatment of hypovolemia
Shock (hemorrhagic, septic)
Hypoproteinemia (as an adjunct to crystalloids)
Improvement of microcirculation in pancreatitis

Horse (Equine)

Treatment of hypovolemia
Shock (endotoxemic, hemorrhagic)
Hypoproteinemia (e.g., in neonatal foals with failure of passive transfer)
Support during colic surgery

Cattle (Bovine)

Treatment of hypovolemia
Shock (septic, hemorrhagic)
Hypoproteinemia (e.g., in calves with diarrhea)

Small Ruminants (Sheep / Goat)

Treatment of hypovolemia
Shock (septic, hemorrhagic)
Hypoproteinemia

Rabbit & Small Mammals

Treatment of hypovolemia
Shock (hemorrhagic, septic)

Exotic & Other Species

Reptiles: limited data; may be used for hypovolemia in critical care. Small mammals (ferrets, guinea pigs): treatment of hypovolemia and shock.

Pharmacology & Mechanism of Action

Drug Class: Synthetic colloid | Pharmacological Group: Hydroxyethyl starch (HES)

Mechanism of Action: Hetastarch is a synthetic colloid composed of hydroxyethyl-substituted amylopectin. It exerts its oncotic effect by increasing the colloid osmotic pressure of plasma, thereby drawing fluid from the interstitial space into the intravascular compartment. This expands plasma volume and improves tissue perfusion. The hydroxyethyl groups on the glucose units slow hydrolysis by amylase, prolonging the intravascular residence time compared to natural starch. Hetastarch also reduces blood viscosity and improves microcirculation by decreasing erythrocyte aggregation and platelet adhesion.

Pharmacodynamics: Hetastarch produces a dose-dependent expansion of plasma volume, with a volume effect roughly equivalent to the volume infused (100% volume effect) initially, which may persist for 24 hours or longer. It improves hemodynamic parameters such as cardiac output, blood pressure, and tissue oxygenation. It has a mild antithrombotic effect due to reduction in von Willebrand factor and factor VIII levels, which can affect coagulation. Hetastarch also has a mild anti-inflammatory effect by reducing capillary leakage and endothelial activation.

⚡ Pharmacokinetics Summary

Absorption: Hetastarch is administered intravenously; absorption phase is not applicable as it is directly introduced into the bloodstream.

Distribution: Hetastarch remains largely within the intravascular space initially, but smaller molecules may extravasate into the interstitial space. It is distributed throughout the body, with highest concentrations in the reticuloendothelial system (liver, spleen). It does not cross the blood-brain barrier significantly.

Metabolism: Hetastarch is slowly hydrolyzed by alpha-amylase in the blood into smaller hydroxyethyl starch molecules. The rate of hydrolysis depends on the degree of substitution; hetastarch has a molar substitution of 0.7, which slows degradation. The smaller fragments are then metabolized in the liver and other tissues.

Excretion: The metabolites are excreted primarily via the kidneys. A small portion may be excreted in the feces via biliary secretion. The elimination half-life is prolonged in patients with renal impairment.

Half-Life: Dogs: approximately 2-4 hours for the initial phase, but the terminal half-life may be 24-48 hours. Cats: similar to dogs. Horses: approximately 10-12 hours. Humans: 17 days for the large molecules, but clinical effect lasts 24-36 hours.

Bioavailability: Not applicable; administered intravenously, so bioavailability is 100%.

Protein Binding: Hetastarch does not bind significantly to plasma proteins.

Available Formulations & Strengths

Injectable Solution 6% in 0.9% Sodium Chloride (e.g., 500 mL, 1000 mL bags) (IV)

Injectable Solution 6% in Lactated Ringer's Solution (e.g., 500 mL, 1000 mL bags) (IV)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to hydroxyethyl starch
Severe coagulopathies (e.g., von Willebrand disease, thrombocytopenia)
Congestive heart failure
Renal failure with oliguria or anuria
Intracranial bleeding
Severe hypernatremia or hyperchloremia (if in saline)
Pregnancy (unless clearly needed)

Warnings & Clinical Precautions:

Use with caution in patients with renal impairment; may worsen renal function.
May interfere with platelet function and coagulation factors; monitor coagulation parameters if used in large volumes.
Risk of volume overload, especially in cats and small animals; monitor central venous pressure and respiratory rate.
May cause anaphylactoid reactions; discontinue infusion if signs of hypersensitivity occur.
Use with caution in animals with liver disease, as metabolism may be impaired.
Not recommended for use in animals with severe sepsis due to increased risk of renal injury.
Do not mix with other medications unless compatibility is known.
Use within 24 hours of opening the bag; discard unused portion.

Adverse Effects & Reactions

Common:

Vomiting
Diarrhea
Pruritus
Mild prolongation of bleeding time
Transient hypotension (if infused too rapidly)

Serious / Severe:

Acute kidney injury
Coagulopathy (decreased factor VIII and von Willebrand factor)
Anaphylaxis
Pulmonary edema
Volume overload
Central pontine myelinolysis (rare, with rapid correction of hyponatremia)

Rare:

Hepatotoxicity
Pancreatitis
Skin necrosis
Hyperamylasemia (may interfere with amylase measurements)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Anticoagulants (e.g., heparin, warfarin)	Additive effect on coagulation inhibition; increased risk of bleeding.	High
NSAIDs	Increased risk of gastrointestinal bleeding and renal impairment.	Moderate
Aminoglycosides	Increased risk of nephrotoxicity.	Moderate
Corticosteroids	Increased risk of fluid retention and electrolyte imbalances.	Mild
Other plasma expanders (e.g., dextrans)	Additive volume expansion and potential for coagulation abnormalities.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Volume overload (pulmonary edema, peripheral edema)
Coagulopathy (prolonged bleeding time, petechiae)
Renal impairment (oliguria, azotemia)
Hypotension (if infused too rapidly)
Hypervolemia leading to congestive heart failure

Emergency Treatment Protocol: Discontinue infusion immediately. Provide supportive care: administer oxygen, diuretics (e.g., furosemide) to manage fluid overload, and monitor renal function. In severe cases, hemodialysis may be considered to remove the starch molecules. Coagulopathy may require fresh frozen plasma or cryoprecipitate if bleeding occurs. Treat anaphylaxis with epinephrine and antihistamines if present.

Food Animal Withdrawal Times

🥩 Meat: 0 days🥛 Milk: 0 days🥚 Eggs: 0 days

Hetastarch is not approved for food animals in many countries; however, due to its short half-life and lack of residues, a zero withdrawal time is often assigned. Check local regulations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (15-30°C). Do not freeze.

Handling & Special Conditions: Protect from freezing. Use only if solution is clear and container undamaged. Discard unused portion after opening.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use. In some countries, it may be approved for veterinary use.

Extra-Label (Off-Label) Use: In the US, hetastarch is not FDA-approved for veterinary use, but it can be used legally under the Animal Medicinal Drug Use Clarification Act (AMDUCA) in animals, provided it is prescribed by a veterinarian within a valid veterinarian-client-patient relationship. Extra-label use in food animals requires a withdrawal period established by the veterinarian, but due to lack of residues, a zero withdrawal time is often assigned.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Hetastarch is a valuable synthetic colloid for rapid plasma volume expansion in veterinary critical care. It is particularly useful in hypovolemic shock when crystalloids alone are insufficient. However, its use has become controversial due to concerns about renal toxicity and coagulopathy, especially in septic patients. In veterinary medicine, it is often used at lower doses (5-10 mL/kg) to minimize adverse effects. It should be used with caution in animals with pre-existing renal disease, coagulopathies, or heart disease. Monitoring of blood pressure, central venous pressure, urine output, and coagulation parameters is recommended during therapy. Hetastarch should not be used as a routine fluid for maintenance; it is reserved for acute resuscitation. In cats, lower doses are recommended due to their sensitivity to volume overload. In horses, it is commonly used in neonatal foals with failure of passive transfer and hypoproteinemia. Always consider the individual patient's fluid status and underlying disease when choosing hetastarch over other colloids or crystalloids.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)